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Abstract
This review article is based on specifically targeted nanoparticles that have been used in the treatment of melanoma. According to
the Skin Cancer Foundation, within 2017 an estimated 9730 people will die due to invasive melanoma. Conventional treatments
for nonmalignant melanoma include surgery, chemotherapy, and radiation. For the treatment of metastatic melanoma, 3 ther-
apeutic agents have been approved by the Food and Drug Administration: dacarbazine, recombinant interferon a-2b, and high-
dose interleukin 2. Photodynamic therapy is an alternative therapy that activates a photosensitizer at a specific wavelength forming
reactive oxygen species which in turn induces cell death; it is noninvasive with far less side effects when compared to conventional
treatments. Nanoparticles are generally conjugated to photosynthetic drugs, since they are biocompatible, stabile, and durable, as
well as have a high loading capacity, which improve either passive or active photosensitizer drug delivery to targeted cells.
Therefore, various photosynthetic drugs and nanoparticle drug delivery systems specifically targeted for melanoma were analyzed
in this review article in relation to either their passive or their active cellular uptake mechanisms in order to deduce the efficacy of
photodynamic therapy treatment for metastatic melanoma which currently remains ongoing. The overall findings from this review
concluded that no current photodynamic therapy studies have been performed in relation to active nanoparticle platform
photosensitizer drug carrier systems for the treatment of metastatic melanoma, and so this type of research requires further
investigation into developing a more efficient active nano-photosensitizer carrier smart drug that can be conjugated to specific cell
surface receptors and combinative monoclonal antibodies so that a further enhanced and more efficient form of targeted pho-
todynamic therapy for the treatment of metastatic melanoma can be established.
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Introduction
Cancer
Cancer is caused by environmentally induced gene mutations,
which in turn trigger cells to proliferate at an abnormally rapid
pace.1 These rapid abnormal proliferations of the cells produce
either benign or malignant tumors.2 Cancer classification is
determined by 4 factors: the type of cell which the tumor
resembles, the tumors origin, the stage of the tumor, and the
current location of the tumor.3
Malignant tumors often spread to surrounding tissues and
move throughout the body using circulatory or lymphatic
systems, causing metastasis.4 Due to the ability of cancer to
metastasize, this makes localized treatment redundant and
therefore problematic in the annihilation of the cancer cells.5
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Due to the amount of new cases diagnosed annually, cancer
is one of the most predominant health threats to individuals.6
There are multiple conventional cancer treatments available
such as surgery, chemotherapy, and radiotherapy or a combi-
nation; they are reliant on the type, location, and stage of the
cancer.7 Additionally, these treatments often are invasive and
induce severe side effects in patients.3 Thus, the investigation
into alternative forms of treatment need to be executed in order
to develop new therapies that can possibly mitigate these
unwanted side effects.3
Metastatic Melanoma
Skin cancers are identified and named according to the cell
from which they originated from as well as their clinical beha-
vior.8 The 3 general types of skin cancer are basal cell carci-
nomas, squamous cell carcinomas, and cutaneous malignant
melanomas.9 The first 2 types are commonly referred to as
nonmelanocytic or noninvasive skin cancer, since they don’t
originate in skin melanocytes and don’t spread to surrounding
healthy tissues.10 However, cutaneous malignant melanomas
tend to spread to surrounding tissues and so are considered to
be metastatically invasive.11
Melanoma is an invasive and aggressive form of skin can-
cer; which is known for its elevated multidrug resistance, very
low rate of patient survival, and tendency to relapse with
ease.12 According to the Skin Cancer Foundation, it is esti-
mated that in 2017 roughly 87 110 new cases of metastatic
melanoma will be diagnosed within the United States alone
and that an estimated 9730 people will die from it due to its
invasiveness.13
Melanoma originates in the deepest regions of the epidermis
and in the beginning regions of the dermis, where melanocytes
that produce melanin pigment are located.5 Thus, it develops
from a single melanocyte that is either malignantly transformed
or by the dysfunction of dysplastic nevi.14
Metastatic melanoma is considered to be a late form of
stage IV of skin cancer and occurs when cancerous cells in
the epidermis metastasize and progress to other organs of
the body that are located far from the original site.5 It is
crucial to diagnose melanoma in its early stages before it
metastasizes, as once it has spread, it is difficult to locate its
origin and so treatment and patient’s survival rate tends to
be hindered.15
The most common cause of melanoma is attributed to ultra-
violet radiation (UV) exposure, family history, and personal
history of melanoma.16 In 2016, the World Health Organization
reported that the incidence of skin cancer is on the rise due to
the excessive UV rays that individuals are being exposed to.
Additionally, lighter skinned patients who have lack of skin
pigmentation have a much higher risk of getting nonmelanoma
or melanoma skin cancers than compared to dark-skinned
patients, due to their increased risk of UV-induced sunburn
skin damage.11
Conventional Treatments for
Metastatic Melanoma
Prognoses of metastatic melanoma are performed by utilizing a
staging classification system that assesses and describes the
degree of disease development in patients (AJCC, American
Joint Committee on Cancer).17 The main factors of this staging
system are location of the primary tumor; tumor size, number
of tumors, lymph node involvement; and the absence or pres-
ence of metastasis.18 In order to determine the stage of cancer,
assessments such as physical examinations, imaging tests,
laboratory tests, and pathology reports are performed on
patients.17 Conventional treatments for metastatic melanoma
include surgery, chemotherapy, radiation, and biological
therapy.5
Surgery
The primary treatment for melanoma is surgery, whereby the
lesion is excised with some of the unaffected surrounding tis-
sues to ensure all the affected tissue is removed and no cancer-
ous cells are present in the area to proliferate.5 Surgery offers
the best chance of recovery if the melanoma has been diag-
nosed within its early stages and has not yet had a chance to
metastasize.19
Chemotherapy
The next conventional treatment for cancer is chemotherapy,
which has the ability to alleviate, control, or completely cure
skin cancer; its success is dependent on the patient’s severity of
the cancer at time of diagnosis.20
Chemotherapy relies on effective drugs to stop cancer cells
from proliferating abnormally or to slow down their overall
growth rate.21 Metastatic melanoma chemotherapeutic drugs
include dacarbazine (DTIC), paclitaxel, platinum compounds,
and temozolomide.22 According to Tang et al,23 malignant
melanomas show <20% response rate to these types of drugs
due to various resistance mechanisms. Chemotherapeutic drugs
may be administered orally, via injection, intraperitoneal, intra-
arterial, topically, or intravenously.23 The drawback to che-
motherapy is that it also causes damage to healthy cells as well
as severe side effects in patients such as fatigue, secondary
infections, anemia, nausea, vomiting, and constipation.24 Thus,
chemotherapy sessions are generally spread out during a period
of time to allow patients’ bodies to recover between treat-
ments.25 Chemotherapy can solely be administered to patients;
it is usually administered either after surgery or in combination
with other treatments such as radiation or biological therapy.20
Radiotherapy
Radiotherapy is another therapy that is used for the treatment of
melanoma.26 It is similar to chemotherapy in the sense that it
can alleviate, control, or cure cancer depending on the severity
and type of cancer the patient has been diagnosed with.27 In this
type of therapy, radiation is employed to annihilate cancer cells
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through external or internal administration.28 With internal
administration, radiation is precisely administered only to the
affected area of a patient’s body, whereas with external radia-
tion the beam is applied to a much wider area and so is con-
sidered less precise.28 Radiation therapy causes side effects
such as skin changes, fatigue, and nausea as well as affects
healthy surrounding tissues.24 Depending on the severity and
type of cancer, a patient can undergo radiation therapy that may
be applied in combination with chemotherapy, and this often
induces far harsher side effects.29
Biological Therapy
Biological therapies also rely on drugs to cure cancer.3 Bio-
logical therapies differ from chemotherapy, since the drugs
that are administered to patients aid the immune system in
combating the cancer rather than just directly killing rapidly
proliferating cells.30 This type of therapy is often used in
combination with other therapies.3 Currently, the Food and
Drug Administration (FDA) has only approved 3 conven-
tional biological agents for the treatment of advanced meta-
static melanoma: DTIC—approved in 1975; recombinant
interferon a-2b—approved in 1995; and high-dose interleukin
2—approved in 1998.31
Unconventional Treatments for
Metastatic Melanoma
Molecular-Targeted Therapy and Immunotherapy
Molecular-targeted therapy uses anti-cytotoxic T-lymphocyte
antigens (CTLA-4) antibodies to target CTLA-4; they are over-
expressed on activated T-lymphocytes and so act as a negative
regulator of T-cell activation.32 This enhances the immune
system’s ability to destroy cancer cells.32 This type of immu-
notherapy treatment targets programmed death 1 and pro-
grammed death ligand 1 or 2 as well as CTLA-4 in
metastatic melanoma cancer cells.33 The problem associated
with this type of therapy is that the overall treatment is not
effective for all patients, as it is influenced by immune-
related side effects and resistance factors.34 Studies performed
by Cirenajwis et al35 evaluated the effects of ipilimumab as an
anti-CTLA-4 inhibitor to effectively treat metastatic melanoma
in patients; however, severe side effects were noted. Thus, in
order to make this type of malignant melanoma treatment more
efficient, it is essential to improve the molecular targeting abil-
ities of the treatment, as well as overcome resistance.36
Nanodrugs
Recent advances in research have exploited the use of nano-
technology for the treatment of cancer; this enhances targeted
cancer cell drug delivery and uptake and drastically reduces
their overall cytotoxic side effects to normal tissues.37 Some
nanodrugs have already been FDA approved for use in precli-
nical and clinical trials, as they have been shown to either target
and directly kill tumor cells or improve overall targeted che-
motherapy drug delivery.38
Photodynamic Therapy
Photodynamic therapy (PDT) has been investigated for the past
30 years as an unconventional treatment for cancer.39 It
involves the administration of photosensitizer (PS) light-
sensitive drug to targeted cancer cells, and the localization of
laser light at an appropriate wavelength is used to excite the
PS.40 The excitation of the PS causes the production of cyto-
toxic reactive oxygen species (ROS), such as singlet molecular
oxygen, hydroxyl radicals, and/or superoxide anions, which
achieve photocytotoxicity through oxidatively stressing cancer
cells and so induces damage to their cellular biomolecules (ie,
lipids, proteins, and nucleic acids), rendering them inactive.41
This unconventional form of treatment is less invasive than
conventional forms of cancer treatment; it specifically targets a
cancerous tumor region and so produces localized destruction
with limited side effects.42
Mechanism of PDT action. There are 2 types of action mechan-
isms in PDT, which occurs in an oxygen-dependent environ-
ment. Both types produce oxygen; however, type 1 reactions
produce superoxide anion radical, whereas type 2 produces a
singlet oxygen.43 Factors that determine this mode of action
includes: PS concentration, PS localization, amount of adeno-
sine triphosphate within the cell, the genetic makeup of the cell
as well as the fluence and wavelength of laser light exposure.41
The modality of PDT, as shown in Figure 1, entails a PS that
is activated at a specific wavelength inducing excitation. In the
excited state also known as a triplet state, 2 types of reactions
occur. In type I reaction, a superoxide anion radical is pro-
duced, and these interact with oxygen to produce oxygenated
products. In type II reactions, the triplet can transfer its energy
directly to the oxygen, therefore producing a singlet oxygen; it
is considered a highly ROS.43
Mechanism of PDT facilitated cell death cytotoxicity. During the
mechanism of PDT action, the ROS that is generated induces
an apoptotic, autophagy, and/or necrotic mode of cell death
(Figure 2).44 Factors that influence the mode and degree of cell
death include cellular morphology, immunological responses,
enzymatic activity, light wavelength and intensity, oxygen con-
centration, and PS physiochemical characteristics as well as PS
subcellular location.45 These factors determine whether the
mode of cell death is nonprogrammed or programmed.41
Apoptosis is a programmed mode of cell death that is usu-
ally characterized by membrane and nuclear degradation.46
The PSs generally tend to localize in cellular mitochondria
when this form of cell death occurs, and it is the most common
associated mode of cell death in PDT.47 Apoptosis in target
cells is activated by specific signals that trigger a variety of
pathways to commit suicide in response to these signals.48 As
the pathways collapse, protein caspases are activated to
degrade cellular contents such as nucleic and polypeptide
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material.49 Therefore, apoptosis is a regulated process that is
induced.50
Necrosis is a nonprogrammed mode of cell death that is
characterized by inflammatory responses, which are initiated
from external stimuli such as infections or trauma.51 The PS
that induces necrosis tend to localize within the plasma mem-
brane of target cells.52 Necrotic cell death pathways events
involve membrane permeability, movement of calcium ions
across the endoplasmic reticulum, cytoplasmic swelling (onco-
sis), calcium-dependent calpain activation, lysosomal rupture,
followed by the breaking down of cell component, and overall
induction of inflammatory responses.53 Within eukaryotic cells
cell death, it is regulated by transduction and catabolic activi-
ties that use receptor interacting proteins.54 Photodynamic
therapy-induced apoptotic modes of cell death can sometimes
be converted to necrosis when conditions such as a high
Figure 2. Different forms of cell death that can be induced in photodynamic therapy (PDT) cancer treatments, namely, apoptosis, autophagy,
and/or necrosis.
Figure 1. The electron and energy transfer during photodynamic therapy (PDT).
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concentration of PS is administered to target cells or very high
fluencies are used to excite the PS.55 These can cause the cell to
rapidly disintegrate and die when compared to apoptotic pro-
grammed cell death.55
However, recent studies by Dewaele and colleagues56 have
noted that after PDT irradiation of certain PSs, another mode of
cell death known as autophagy can be induced. Photodynamic
therapy-induced autophagy occurs when a cell attempts to
repair itself to overcome photoinjury; however, if this response
fails then the cell is signaled for programmed apoptosis.57
Photodynamic therapy challenges. Some challenges faced when
PDT is applied to cancer treatments (to ensure its effectiveness)
include applying the correct wavelength and exposure time to
maximally excite a specific PS to ensure the highest yield
production of ROS.58 Additionally, the concentration and loca-
lization of PSs, which is taken up by target cells, is important to
ensure that maximum levels of ROS can be generated to induce
maximum cell death.59 If passive diffusion via the enhanced
permeability and retention (EPR) effect is utilized as a mode of
PS drug uptake, PSs do tend to localize more predominantly in
rapidly proliferating tumor cells; however, they also tend to be
absorbed by some healthy surrounding tissues that cause
unwanted side effects.60 Thus, to improve PS tumor selectivity,
as well as the overall efficiency of PDT research, research
nowadays tend to focus more on the development of multi-
component PS drug targeting strategies that enhance PS deliv-
ery and concentration in only specific targeted cells.61 Finally,
sometimes within PDT applications, the ability to access deep-
seated tumors with laser light is problematic, and so alternative
measures and treatments need to be considered for application
in combination with PDT.62
Photodynamic therapy has been successfully used for the
treatment of basal cell carcinoma head and neck cancers which
are over exposed and so easily accessed by laser light irradia-
tion.63 However, skin cancers that have internally metastasized
are far harder to treat with PDT, since they receive far less
exposure to laser light irradiation.64 Additionally, metastatic
melanomas are pigmented with melanin, which does not allow
for efficient laser light to reach the target sight; hence, PDT
treatment for this form of skin cancer is often less effective.65
Nevertheless, recent research developments are currently
focused on developing targeted cellular uptake photosynthetic
drugs, which can be activated by a far higher wavelength with
deeper tissue penetration and improved ROS generation as well
as far more compacted lasers that can deliver light endoder-
mally to overcome these issues.66
Effective PSs Used for Metastatic Melanoma
PDT Treatment
There are different classes of PSs that have been investigated
over the years for PDT treatment of metastatic melanomas.67
When considering which type of PS to apply to a particular
PDT treatment, there are a number of factors that need to be
considered such as its characteristics, its mode of action, where
it localizes as well as what type of cell death it induces.68
Generally, most PSs tend to localize in most cellular orga-
nelles other than the nucleus and so are less likely to induce
carcinogenesis, DNA damage, or mutations.69 The PSs that are
used for PDT applications are divided into 3 generations, which
is dependent on their photochemical and photophysical char-
acteristics in relation to their cellular mode of action.70
First-generation PSs tend to induce vascular tissue damage as
localization, with severe side effects, indicating that their spe-
cific localization in target cells is limited.71 Second-generation
PS tend to cause only tumor cell cytotoxicity, suggesting a
more passive form of PS localization in organelles such as
mitochondria, lysosomes, endoplasmic reticulum, and plasma
membrane.72 Therefore, the side effects induced by second-
generation PSs are far less than those of first-generation PSs.72
Third-generation PSs are photosynthetic drugs that have
been further functionalized by the addition of various targeting
biomolecules to enhance their specific cellular drug uptake
and absorption.73
The 4 main classes of PSs include porphyrins, phthalocya-
nines, chlorins, and porphycenes.72 Porphyrins have been used
excessively in PDT applications, as they are very stable, how-
ever, are of first generations, and so tend to induce photosensi-
tivity and tissue penetration depth is poor.74 Chlorins are
second-generation PSs that are reduced from porphyrin or
chlorophyll derivatives.75 Reports by Jerjes and colleagues76
have noted that chlorins have a high PDT efficacy rate when
treating basal cell carcinomas and squamous cell carcinomas.
Phthalocyanines are second-generation PSs, which have an
even higher PDT efficacy, as they contain a diamagnetic metal
ion that allows for deep laser light tissue penetration with far
less phototoxic side effects.77 Porphycenes are electronic iso-
mers of porphines that are synthetically produced and so
require further investigation into their mode of action as at
present it is not fully understood.78 Table 1 reports on current
PSs that have been investigated and applied for the PDT treat-
ment of metastatic melanoma as well as lists the functional
parameters and outcomes of each study. After the review of
Table 1, it was concluded that the most common PSs that have
been investigated for the PDT treatment of metastatic mela-
noma include those from the phthalocyanines and porphyrin PS
classes; however, in general, metallophthalocyanine PSs seem
to be more promising for the treatment of metastatic melanoma
than porphyrins, as they noted overall less photosensitivity/
phototoxicity.
Nanotechnology and Nanoparticles
Nanotechnology in research has been shown to have an
extremely promising future in cancer drug delivery mechan-
isms.87 This is due to the fact that nanostructures have a large
surface area to volume ratio, allowing drugs to be bound to
nanoparticles (NPs), which act as carriers that promote cellular
uptake.88 Additionally, properties of NPs can be engineered to
exhibit certain properties to assist in drug delivery such as: the
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diameter control, stability, permeability, porosity, and hydro-
philic adaptations.89
Applications of NPs within cancer PDT therapy PS drug
delivery systems are fast becoming effective; they are easy to
synthesize, have high surface area-to-volume ratio (they have
the ability to support a large amount of therapeutic agents), and
have simple surface chemistry with the possibility of functio-
nalization.90 Additionally, due to the small dimensions of NPs,
they can easily accumulate in cells, more specifically in tumor
cells due to the EPR effect.91 The EPR allows NP drug carriers
to enter tiny spaces between tumor cells, suppressing lymphatic
filtration and so the drug uptake in tumor cells is increased.92
The factors that can affect the EPR are the pore dimensions for
the molecule to enter at the tumor site, the tumor location, the
size of the tumor, and the type of tumor which is present;
optimizing NPs as carriers for drug delivery is essential.93
Thus, the incorporation of antibodies or targeting molecules
to NPs can promote PS drug attachment to malignant cell
membranes, cytoplasmic receptor sites, and nuclear receptor
sites, which increases drug uptake in specific tumor cells while
reducing the overall toxicity in healthy cells.94 Additionally,
engineered NPs allow compatibility with the immune system
and therefore tend to go by unnoticed by immune system bar-
riers, as they mimic biological molecules and can combine to
Table 1. The Outcomes and Parameters of PSs’ Used During PDT to Treat Melanoma.
Photosensitizer (PS) Parameters Cells Result Reference
Verteporfin Wavelength: 690 nm;
Fluency: 520 mJ/cm2;
(PS): 5.5 mmol/kg
Melanoma tumors in
mice
Large necrotic areas were seen in tumor and
reduction in tumor growth was observed.
The photosensitivity of Verteporfin is dose-
dependent as higher doses yield prolonged
photosensitivity.
5
10,15,20-tritolylporphyrin-5-
(4-amidophenyl)-[5-(4-
phenyl)-10,15,20-
tritolyporphyrin] (T-D)
Wavelength: 630 nm;
Fluency: 81 J/cm2; (PS):
107 M
Human melanoma
cells (SK-MEL
188); Mouse
melanoma cells
(S91)
Both types of cells showed a 3-fold decrease
in size compared to control cells. It requires
high-energy irradiation for phototoxicity
but has more advantages than Photofrin.
79
5,10,15,20-tetrakis(2,6-
difluoro-3-N-
methylsulfamoylphenyl)
bacteriochlorin
Wavelength: 633 nm;
Fluency: 6.2 J/cm2;
(PS): 20 mM
Mouse melanoma cells
(S91)
S91 cells still destroyed 24 hours post
treatment using vascular-targeted PDT.
Cellular-targeted PDT led to strong pO2
compensatory effects and tumor regrowth.
80
Halogenated porphyrins Wavelength: 633 nm;
Fluency: 10 J/cm2; (PS):
10 mM
Human melanoma
cells (A375)
PS showed a 30-fold increase in killing
efficiency than when compared to
Photofrin, since its halogenated structure
interfered with P-glycoproteins. All
porphyrins present a much higher
phototoxicity than Photofrin.
81
Meso-tetrakis-(4-
sulfonatophenyl) porphyrin
(TPPS4)
Wavelength: 633 nm;
Fluency: 10 J/cm2; (PS):
12.5 mg/mL
Human melanoma
cells (G361)
Most effective sensitizer is ZincTPPS4, since
the IC50 value was 12.5 mg/mL at the dose
of light radiation of 10 J/cm2. According to
the results, ZincTPPS4 seems to be more
phototoxic than TPPS4.
82
5-aminolevulinic acid (5-
ALA)
Wavelength: 420-1400
nm; Fluency: 45 and 90
J/cm2; (PS): 200 g/mL
Mouse melanoma cells
(Mel25)
Effectively killed cells in vitro, however
reported minor effects when tested in vivo.
83
Ruthenium porphyrins Wavelength: 652 nm;
Fluency: 5-30 J/cm2;
(PS): 10 mM
Human melanoma
cells (Me300)
A significant cell death ranging from 60% to
80% decrease in cell viability was noted.
It shows some degree of cytotoxicity in the
dark but seems to present no phototoxicity
upon irradiation.
84
Phthalocyanine Wavelength: 630-780 nm;
Fluency: 10 J/cm2; (PS):
2  109 M
Achromic melanoma
cells (M6)
Significant photo-killing was observed in
cultured cells that was linked to lipid
peroxidation.
85
Metallophthalocyanine (MPc)
and 5-aminolevulinic acid
(5-ALA)
Wavelength: 680 nm;
Fluency: 10 J/cm2; (PS):
4 mM of 5-ALA and 10
mM MPc
Human metastatic
cells (A375)
Significant decreases in cell viability ranging
from 60% to 80% was reported, with a
cytotoxic induction of apoptotic cell death.
However, control cells which received
5-ALA only noted photo toxicity before
irradiation, whereas cells that received MPc
did not.
86
Abbreviations: MPc, metallophthalocyanine; PDT, photodynamic therapy.
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other molecules such as PSs that improve and enhance drug
delivery.90 Moreover, NPs can be further functionalized into
active targeting molecules through the attachment of molecules
that are specifically compatible to targeted tumor cells.95
However, when it comes to pharmaceutical nanotechnology
cancer drug engineering delivery, researchers need to take the
following into consideration such as safety, bioethical issues,
toxicity hazards, and physiological issues. Thus, scientific
researchers must take the following into consideration when
designing functionalized nanotechnology-based drug delivery
systems such as size, characterization, and specific targeting of
diseased tissue only, by selecting antibodies or other means of
selective binding which are only overexpressed in definitive
tumor cells so as to enhance drug delivery and reduce overall
nonspecific toxicity.96
Nano-Drug Delivery Carrier Platforms and
Targeting Strategies for PDT Cancer
Treatment
For effective PDT, functionalized NP platforms need to be used
in order to enhance PS drug delivery, and each type has its own
individual advantages, whether it may be passively or actively
absorbed by tumor cells (Table 2; Figure 3).97 These strategies
enable PSs that are delivered to tumor sites to induce cell
death.98 This type of drug delivery needs to be targeted to
ensure that the PS is only delivered to the tumor target site and
not healthy surrounding tissues to prevent phototoxicity and
unwanted side effects in healthy cells.99
Passive PS absorption is accomplished when the drug accu-
mulates in tumor cells due to NP characteristics such as com-
position and size, and overall drug uptake is only affected by
the surrounding tumor environment (such as hypoxia or low
pH) and EPR effect.100 Examples of NP drug delivery plat-
forms, which passively enhance PS drug accumulation in PDT
applications include: micelles and liposomes, polymeric parti-
cles, dendrimers, metal oxide, ceramic, silica, and alumina
organic-based NP.101
In active absorption, the PS drug is delivered to a spe-
cific target tumor site through a molecular recognition pro-
cess.102 The NPs are functionalized with target molecules
that specifically bind to receptors overexpressed by tumor
cells, leading to enhanced PS drug uptake.103 Targeting
molecules that are exploited in targeting PS drug delivery
to tumor cells include: monoclonal antibodies (mAb), apta-
mers, antibody fragments, peptides, and/or DNA/RNA.104
Examples of NP drug delivery platforms that actively
enhance PS drug targeting in PDT are generally inorganic
nanomaterials such as: quantum dots, solid lipids, self-
illuminating nanocrystals, theranostic, hydrogels, immune-
conjugates, metal-oxide based or upconverted.105
However, studies by Maeda93 have shown that PDT PS
carrying NPs that use a passive targeting strategy tend to some-
times affect healthy surrounding tissues more than active tar-
geting strategies, since passively absorbed NP drugs cannot
exclusively differentiate between cancerous and normal cells
and so occasionally distribute in healthy tissues. Thus, to
improve tumor PS drug accumulation specificity and limit
unwanted side effects, recent research has now focused on
synthesizing specifically targeted activity absorbed NP–PS
bioconjugates for PDT cancer applications.106 However, to
date, this still remains a challenging task as the overall
NP–PS drug delivery is dependent on the size, surface func-
tionalities, and specificity of NP carrier, as well as the NP
disintegration and PSs drug release rate once absorbed by
specifically targeted cells.107
Table 2. NP Platform Passive or Active Drug Carrier Systems, With
Strategic Advantages for PDT Cancer Treatment.
NP Platform Advantages
Passive PDT PS Tumor Drug Absorption
Micelles and Liposomes Enhanced tumor uptake (Liposomes)
and improved tumor phototoxicity
(micelles)87
Polymeric particles
(polyethylene glycol)
High drug loading, biocompatibility,
high drug encapsulation, and better
drug release profile108,109
Dendrimer encapsulated
NP
High drug loading110
Metal oxide NP Higher loading capability,
biocompatibility, and surfaces can
be easily modified with different
functional groups and
nontoxicity111
Ceramic Highly stable, biocompatible, and
hydrophilic112
Silica Surfaces can be easily modified with
different functional groups113
Alumina Highly stable and induce oxidative
stress114
Active PDT PS Tumor Drug Absorption
Quantum dots Large absorbance cross section and
size-tunable optical properties115
Solid lipid Improved stability, better drug
release, high loading capability, and
biocompatible116,117
Self-illuminating
nanocrystals
Uses lower doses of radiation118
Theranostic (biodegradable
photoluminescent poly)
Strong fluorescence and
cytocompatibility. Can be
conjugated with peptide to increase
loading efficiency119
Hydrogels High absorption capability and highly
stable and durable120
Immuno-NP Highly specific molecule, improves
drug release within desired cell121
Cerium oxide, zinc oxide,
copper oxide
Highly selective, radioprotective,
size-tunable optical properties, and
nontoxic122-126
Upconverting Near-infrared optical absorption
coefficients125
Abbreviations: NP, nanoparticle; PDT, photodynamic therapy; PS,
photosensitizer.
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Nanotechnology and Metastatic Melanoma
In terms of the utilization of nanotechnology for the PDT treat-
ment of skin cancer, topical drug delivery can be improved
through NP engineering by understanding the NP drug mode
of delivery and skin interaction.127 The delivery of topical
drugs is achieved through 3 different skin sites that include
open hair follicles, furrows, and the stratum corneum sur-
face.102,128 The skin can become damaged through various
factors such as aging and disease; this in itself is a potential
and ideal route for drug delivery.102 In studies performed by
Naves and colleagues,129,130 it was found that microemulsions
that contained 5-fluorouracil, applied topically allowed an
enhanced drug absorption in patients diagnosed with squamous
cell carcinoma that had ulcerations on their skin surface. Stud-
ies by the Scientific Committee on Consumer Products
reported that NPs which are larger than 20 nm in diameter,
cannot reach viable tissues, however can deeply penetrate hair
follicles, whereas NPs that are less than 10 nm in diameter can
penetrate the skin and reach viable tissue.128 Although NPs
tend to interact in an adherent way with the skin, careful con-
sideration needs to be taken when engineering NP drug deliv-
ery systems in terms of NP size, tumor location, and mode of
delivery to ensure maximum PS drug accumulation occurs only
at the target site.113
Gold NPs (AuNPs) have been extensively investigated in
PDT-induced cancer treatments, as they have tunable optics
and photothermal properties, which allow for the conversion
of laser light into heat improving targeted cellular destruc-
tion.105 Studies Baldea and Filip130 noted that 5-ALA PS drugs
were effectively absorbed and taken up in a 3-fold higher con-
centration within in vitro cultured murine melanoma tumors
than when compared to the photosynthetic drug administration
alone, suggesting that the AuNPs showed overall enhancement
of cellular PS drug uptake. Studies by Brys et al131 investigated
the clinical outcomes in patients having melanoma by admin-
istering pegylated liposomal nanocarries that were conjugated
to Doxorubicin (Doxil®, USA). The study revealed that the
uptake of Doxil, which is an FDA-approved anticancer drug,
Figure 3. Passive and active forms of photosensitizer (PS) nano-drug cancer targeting strategies used in the photodynamic therapy (PDT)
treatment of cancer.
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was improved with enhanced toxicity than when compared to
the standard Doxil uptake control studies that had no nanocar-
rier assistance.131
Nano-PS Drug Targeting Strategies for PDT
Metastatic Melanoma Treatment
Table 3 lists the various types of passive nano-PS drug delivery
carrier platforms that are currently under investigation for the
PDT treatment of metastatic melanoma as well as the resulting
outcomes of these studies. After review of the result findings of
Table 3, it can be concluded that in general metastatic mela-
noma PDT studies have tended to focus on the conjugation of
porphyrins, phthalocyanines, chlorin PSs to gold, magnetic,
silica, and albumin-stabilized passive NP platforms.
In terms of active nanodrug delivery systems to improve the
specific uptake and targeted delivery drugs to metastatic mel-
anoma tumor sites, various NP drug delivery platforms are
currently under investigation, which are functionalized with
mAbs, antibody constructs, or small molecule inhibitors (Table
4).102 These active NP drug delivery systems are specifically
directed at metastatic melanoma cell surface receptors or target
components of the intrinsic signaling pathways of cells to
enhance various forms of treatment.
Studies performed have noted that metastatic melanoma
cells tend to overexpress integrin anß3, extracellular matrix
1, a combination of Drosophilia protein and Caenorhabditis
elegans protein, B-cell lymphoma 2, mitochondrial p32 pro-
tein, integrin alpha 4 beta 1 protein, ephrin type-A receptor 2,
and TRAIL-receptor 2 on their cell surface receptors.23 The
protein melanoma inhibitory activity was identified as a key
component that was involved in the progression and metastasis
of malignant melanoma.143 Thus, active NP–PS smart drugs
can possibly be synthesized with mAbs, which bind using a
lock-and-key mechanism to these specifically overexpressed
cell surface antigen receptors, ensuring PS drugs are delivered
to tumor target sites only and not healthy surrounding tis-
sues.144 Currently, rituximab, bevacizumab, and trastuzumab
are mAbs that are FDA approved and utilized to target meta-
static melanoma cells.144 However, mAb nanotargeting smart
drugs are very expensive to use, and large-scale production is
problematic and challenging due to their physical and chemical
properties that have to undergo detailed characterization and
additionally to ensure that during manufacturing the process,
composition and structure is not altered as this could have
adverse effects.144
It can be observed from Table 4 that no current PDT studies
have been performed in relation to active NP platform PS drug
Table 3. Passive NP Platform PS Drug Carrier Systems, With Resulting Outcomes for PDT Treatment of Metastatic Melanoma.
Conjugated PS Passive NP Platform Result Reference
Phthalocyanine Silica NP Particle size was 28 nm, absorption at 674 nm, reduced and delayed
photobleaching and high efficiency in generation of reactive oxygen
species.
132
Verteporfin Silica NP UV-Vis spectrum showed bands at 425 nm, red light induce singlet
oxygen release and Ver-Mesoporous silica nanoparticles irradiation
resulted in cell line SK-MEL 28 proliferation halving whereas the
same treatment when NP’s internalization was inhibited resulted in
30% reduction in cell growth.
133
5-aminolevulinic
acid (5-ALA)
AuNP A .023 P value was obtained between 5-ALA and the PS-NP conjugate in
fluorescence intensity, cell survival % at (2 mM) of AuNPs showed a
significant difference to (0.25 mM) and (0.5 mM) AuNP. Maximum
cell death was obtained with 60 J/cm2 of irradiation.
134
None AuNP loaded with rose bengal (RB)
and doxorubicin (Dox)
AuNP were found to enhance the singlet oxygen generation rate, with a
maximum enhancement factor of 1.75. Gold-loaded liposomes
containing RB and Dox where Dox release was triggered by light were
found to exhibit higher cytotoxicity compared with the liposomes
loaded with RB and Dox alone.
135
None Mesoporous-silica NP loaded with
dacarbazine
In vitro, nanocarrier exhibited the strongest cytotoxicity to melanoma
cells compared with DTIC-NP and free DTIC. No in vivo studies
performed yet.
136
Hydrophilic
chlorine
Magnetic NP Cell viability measurements demonstrated that PS-MNPs were more
phototoxic than PEI-chlorin p6 against 2 variants of B16 murine
melanoma
137
None Albumin-stabilized paclitaxel Improved progression-free survival compared with dacarbazine
treatment alone
138
None Albumin-stabilized paclitaxel NP
mixture loaded with carboplatin
Improved overall survival compared to ipilimumab 138
5-aminolevulinic
acid (5-ALA)
Chitosan NP Improved stability, enhanced delivery, and superior PDT phototoxicity 139
Abbreviations: AuNP, Gold NPs; DTIC, dacarbazine; NP, nanoparticle; PDT, photodynamic therapy; PS, photosensitizer; UV, ultraviolet radiation.
Naidoo et al 9
carrier systems for the treatment of metastatic melanoma. Thus,
this type of research requires further investigation into devel-
oping a more efficient active nano PS carrier smart drug that
can be conjugated to targeting molecules and combinative
mAbs so that a further enhanced and more efficient form of
targeted PDT for the treatment of metastatic melanoma can be
established.
Conclusion
In recent years, the incidence and mortality rates of metastatic
melanoma are on the rise due to patients being excessively
exposed UV sun rays, as the atmosphere slowly disintegrates.
Currently, metastatic melanoma remains a very difficult form
of cancer to cure, and overall the findings from this review
suggest that neither conventional nor unconventional treat-
ments used in singular approaches are promising.
Recent research is showing promising results in terms of
using combination therapeutic treatments with actively specific
NP platform carrier systems which can target metastatic mel-
anoma tumors. This type of research needs further investigation
in terms of PDT applications, whereby PS that have previously
been examined (Table 1) for metastatic melanoma, are conju-
gated to various NP platforms (Tables 2 and 4), which have
been functionalized with mAbs, antibody constructs, or small
molecule inhibitors to effectively enhance the active uptake of
photosynthetic drugs in metastatic melanoma cells, increasing
its concentration and overall induced PDT cell death within
tumor cells only, with limited side effects.
Presently, there are some newly developed conventional
therapeutic agents in preclinical trials; however, the search for
the cure of metastatic melanoma remains ongoing and actively
targeted PDT unconventional treatments do seem to possibly
have a probability of enhancing treatment for metastatic mel-
anoma within the near future of applied research.
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